Eligible participants will be pediatric (<18 years) and adult patients (aged 18 years or older) with B-cell malignancies who have received tisagenlecleucel through the commercial setting or out-of-specification (OOS) use in Brazil. We will collect data prospectively and complement missing information with retrospective data collection, when necessary.~It is anticipated that approximately 200 patients will be enrolled in the cohort over 5 years, with at least 100 lymphoma patients who received tisagenlecleucel for the treatment of relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL).~Since this is a non-interventional study, no administration of study drug or application of questionnaires will be mandated by this protocol. The study will consist of a Pre-infusion and a Post infusion follow-up period for up to 15 years post tisagenlecleucel infusion. All patients will be followed until death or last scheduled visit, whichever comes first.~For the study, pre-infusion and follow-up post infusion phases are defined as:~Pre-infusion will consist of the patient's information from the time of diagnosis until just prior to infusion with tisagenlecleucel.~Follow-up Post infusion information will comprise any information from the infusion of tisagenlecleucel onwards.
This post-authorization safety investigation will be a multicenter, non-interventional, prospective cohort study.